Abeona Therapeutics (ABEO) Competitors $6.90 -0.01 (-0.07%) As of 03:01 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ABEO vs. ARDX, HROW, SPRY, SDGR, AMPH, VERA, ABCL, ETNB, SNDX, and COGTShould you be buying Abeona Therapeutics stock or one of its competitors? The main competitors of Abeona Therapeutics include Ardelyx (ARDX), Harrow (HROW), ARS Pharmaceuticals (SPRY), Schrodinger (SDGR), Amphastar Pharmaceuticals (AMPH), Vera Therapeutics (VERA), AbCellera Biologics (ABCL), 89BIO (ETNB), Syndax Pharmaceuticals (SNDX), and Cogent Biosciences (COGT). These companies are all part of the "pharmaceutical products" industry. Abeona Therapeutics vs. Its Competitors Ardelyx Harrow ARS Pharmaceuticals Schrodinger Amphastar Pharmaceuticals Vera Therapeutics AbCellera Biologics 89BIO Syndax Pharmaceuticals Cogent Biosciences Abeona Therapeutics (NASDAQ:ABEO) and Ardelyx (NASDAQ:ARDX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings. Which has stronger valuation & earnings, ABEO or ARDX? Ardelyx has higher revenue and earnings than Abeona Therapeutics. Ardelyx is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAbeona Therapeutics$400K883.92-$63.73M$0.709.85Ardelyx$386.15M3.96-$39.14M-$0.23-27.59 Which has more risk and volatility, ABEO or ARDX? Abeona Therapeutics has a beta of 1.55, indicating that its stock price is 55% more volatile than the S&P 500. Comparatively, Ardelyx has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500. Does the media prefer ABEO or ARDX? In the previous week, Ardelyx had 13 more articles in the media than Abeona Therapeutics. MarketBeat recorded 18 mentions for Ardelyx and 5 mentions for Abeona Therapeutics. Ardelyx's average media sentiment score of 0.70 beat Abeona Therapeutics' score of 0.66 indicating that Ardelyx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abeona Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Ardelyx 9 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer ABEO or ARDX? Abeona Therapeutics presently has a consensus target price of $19.50, suggesting a potential upside of 182.81%. Ardelyx has a consensus target price of $11.50, suggesting a potential upside of 81.25%. Given Abeona Therapeutics' higher possible upside, research analysts plainly believe Abeona Therapeutics is more favorable than Ardelyx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abeona Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Ardelyx 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00 Is ABEO or ARDX more profitable? Abeona Therapeutics has a net margin of 0.00% compared to Ardelyx's net margin of -14.60%. Abeona Therapeutics' return on equity of 89.05% beat Ardelyx's return on equity.Company Net Margins Return on Equity Return on Assets Abeona TherapeuticsN/A 89.05% 45.64% Ardelyx -14.60%-36.57%-13.42% Do insiders & institutionals hold more shares of ABEO or ARDX? 80.6% of Abeona Therapeutics shares are owned by institutional investors. Comparatively, 58.9% of Ardelyx shares are owned by institutional investors. 6.9% of Abeona Therapeutics shares are owned by insiders. Comparatively, 4.8% of Ardelyx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryAbeona Therapeutics beats Ardelyx on 10 of the 16 factors compared between the two stocks. Get Abeona Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ABEO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ABEO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABEO vs. The Competition Export to ExcelMetricAbeona TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$353.57M$3.06B$5.75B$9.85BDividend YieldN/A2.26%3.95%4.02%P/E Ratio9.8521.1531.3126.63Price / Sales883.92383.94459.79120.56Price / CashN/A44.4437.7659.36Price / Book2.168.0810.026.70Net Income-$63.73M-$54.08M$3.27B$265.68M7 Day Performance-3.02%2.44%3.26%3.46%1 Month Performance4.15%3.56%4.45%1.11%1 Year Performance24.46%18.78%44.34%24.00% Abeona Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABEOAbeona Therapeutics4.4292 of 5 stars$6.90-0.1%$19.50+182.8%+23.2%$353.57M$400K9.8590ARDXArdelyx4.1399 of 5 stars$5.81-2.7%$11.50+97.9%-0.5%$1.44B$333.61M-25.2690News CoverageInsider TradeHROWHarrow3.4433 of 5 stars$38.32-1.3%$64.67+68.8%-10.6%$1.44B$199.61M-153.28180Analyst RevisionSPRYARS Pharmaceuticals2.4031 of 5 stars$14.03-3.4%$31.00+121.0%-3.7%$1.44B$89.15M-28.6390SDGRSchrodinger2.8535 of 5 stars$20.05+3.5%$27.83+38.8%-4.0%$1.43B$207.54M-8.08790Positive NewsAMPHAmphastar Pharmaceuticals3.396 of 5 stars$29.76-0.2%$31.50+5.8%-37.1%$1.39B$731.97M11.152,028News CoverageAnalyst ForecastVERAVera Therapeutics3.8356 of 5 stars$21.80+1.2%$63.00+189.0%-41.5%$1.37BN/A-6.0940News CoveragePositive NewsABCLAbCellera Biologics2.2858 of 5 stars$4.67+1.7%$8.00+71.3%+66.7%$1.37B$28.83M-8.49500News CoverageGap UpETNB89BIO2.34 of 5 stars$9.44+2.3%$26.29+178.5%+2.2%$1.37BN/A-2.6140News CoverageAnalyst ForecastSNDXSyndax Pharmaceuticals3.923 of 5 stars$15.87+0.8%$38.00+139.4%-21.9%$1.36B$23.68M-4.08110Positive NewsCOGTCogent Biosciences3.5177 of 5 stars$12.11+1.9%$18.70+54.4%+24.2%$1.35BN/A-6.8080News CoveragePositive NewsAnalyst Forecast Related Companies and Tools Related Companies Ardelyx Alternatives Harrow Alternatives ARS Pharmaceuticals Alternatives Schrodinger Alternatives Amphastar Pharmaceuticals Alternatives Vera Therapeutics Alternatives AbCellera Biologics Alternatives 89BIO Alternatives Syndax Pharmaceuticals Alternatives Cogent Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ABEO) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredThis strange black card is showing up across America"THIS is the Biggest Economic Story of 2025" While most Americans are focused on tariffs and inflation, the...Stansberry Research | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abeona Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Abeona Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access